McKesson Corp. is overhauling its organizational structure and reportable segments in a way to accelerate growth in higher-margin businesses and give investors clearer insight into its operations. The changes will take effect in the second quarter of fiscal 2026.
The company said it will now be organized around four core reportable segments: North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, with a small “Other” category for operations being sold. The move combines McKesson’s U.S. and Canadian pharmaceutical distribution businesses under a single umbrella, while creating a dedicated segment focused on oncology and specialty provider services — areas the company described as central to its growth strategy.
“McKesson has a long history of leadership in healthcare, continuously evolving to meet the needs of our customers, providers, and the patients we collectively serve,” said Chief Financial Officer Britt Vitalone. “This updated reporting structure reflects a strategic evolution of our business — accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services. It enhances transparency and reinforces our disciplined approach to capital allocation and shareholder value creation.”
The new Oncology and Multispecialty segment will encompass specialty drug distribution, group purchasing organizations, and practice management services for community-based oncology networks, along with solutions for other specialty providers such as retina and ophthalmology practices. It will also include clinical trial services, specialty pharmacy offerings, and technology-driven data insights.
The North American Pharmaceutical segment will oversee McKesson’s large-scale drug distribution operations serving retail pharmacies, community pharmacies, and institutional healthcare providers. Prescription Technology Solutions will continue to link patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies through digital networks designed to improve medication access and affordability.
Medical-Surgical Solutions, which supplies medical-surgical products and logistics to healthcare providers in alternate care settings, will remain a standalone segment as McKesson continues plans announced earlier this year to separate it into an independent company.
The company’s remaining operations in Norway will be classified as “Other” until their planned sale closes, following a definitive agreement signed on August 4, 2025.
Don’t miss any content from Distribution Strategy Group. Join our list.
